drugset / Trial / NCT01969318
Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindPrevention
Summary
SP2086 is a new dipeptidyl peptidase(DPP)-4 inhibitor. This study aims to evaluate the efficacy and safety of SP2086 in combination therapy with Metformin in patients with Type 2 Diabetes in Metformin monotherapy Who have Inadequate Glycemic Control
Timeline
- Start
- 2012-03
- Primary completion
- 2012-08
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retagliptin | Small molecule | 50 mg | — |
| Subject | Retagliptin | Small molecule | 100 mg | — |
| Comparator | Metformin | Small molecule | 500 mg | Oral |